Use of Acetylcysteine in the Treatment of Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome
DOI:
https://doi.org/10.30841/2307-5090.3.2020.215984Keywords:
chronic prostatitis/chronic pelvic pain syndrome, acetylcysteine, quercetin, fertilityAbstract
Antioxidants are recommended for the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The efficacy and safety of quercetin in the treatment of patients with CP/CPPS have been studied most. To increase the effectiveness of treatment, we propose to use acetylcysteine, which, along with antioxidant properties, has secretolytic properties.
The objective: to provide a comparative assessment of the efficacy and safety of quercetin and acetylcysteine in the treatment of patients with CP/CPPS.
Materials and methods. The study involved 60 patients with CP/CPPS aged 18–45 years. Patients were randomized into two comparison groups. Patients in group 1 (n=30) were prescribed quercetin1 g per day for 1 month. Patients in group 2 (n=30) received acetylcyteine orally at a dose of 600 mg per day for 1 month. The condition of patients was assessed according to the NIH-CPSI scale, spermogram parameters and dynamics interlekin-10 (IL-10) and tumor necrosis factor α (TNF-α) in ejaculate. The efficiency criterion was considered to be a 25 % decrease in the NIH-CPSI.
Results. As a result of the treatment of patients with CP/CPPS with the use of antioxidants in both groups symptoms of the prostatitis were reduced: NIH-CPSI total (group 1 – 22,5±0,5 vs. 15,0±0,8; group 2 – 22,7±0,5 vs. 15,1±1,1); pain (group 1 – 11,5±0,3 vs. 7,1±0,4; group 2 – 10,0±0,5 vs. 6,6±0,6); urinary symptoms (group 1 – 3,4±0,3 vs. 2,1±0,2; group 2 – 4,8±0,4 vs. 2,2±0,4), quality of life (group 1 – 7,7±0,4 vs. 5,8±0,3; group 2 – 7,8±0,3 vs. 6,3±0,4). The fertility was improved significantly (p<0,05): increased sperm concentration, progressive sperm motility, decreased number of pathological sperm, leukocyte TNF-α concentration and increased IL-10 concentration in ejaculate. In group 2 only ejaculate viscosity decreased significantly (p<0,05), improved sperm motility, decreased white blood cell count, decreased TNF-α concentration in ejaculate were significantly greater than in group 1. The clinical efficacy of acetylcysteine and quercetin in the treatment of patients with CP/CPPS was 63,3 % and 60,0 % respectively (subject to the efficacy criterion of reducing the NIH-CPSI score by 25 %).
Conclusion. The use of acetylcysteine can be useful for patients with CP/CPPS.References
Castiglione R., Salemi M., Vicari L.O., Vicari E. Relationship of semen hyperviscosity with IL-6, TNF-α, IL-10 and ROS production in seminal plasma of infertile patients with prostatitis and prostato-vesiculitis // Andrologia. – 2014 Dec;46(10):1148–55. doi: 10.1111/and.12207. Epub 2013 Dec 16.
Shoskes D.A., Zeitlin S.I., Shahed A., Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial //Urology. – 1999. – N 54 (6). – P. 960–963.
Lv C., Zhong Z., Wu Z. et al. Non-bacterial prostatitis in Kunming mouse induced by long-term stimuli of passive sexual abstinence. J. Androl. – 2010. – N 31 (3). – P. 244–249.
Ломоносов С.П. Ацетилцистеин в лечении острых и хронических заболеваний органов дыхания // Укр. мед. часопис. – 1999. – № 1 (9). – С. 100–102.
Wang L.L., Huang Y.H., Yan C.Y., Wei X.D., Hou J.Q., Pu J.X., Lv J.X. N-acetylcysteine Ameliorates Prostatitis via miR-141 Regulating Keap1/Nrf2 Signaling // Inflammation. – 2016. – N 39 (2). – P. 938–947.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 І. І. Горпинченко, К. Р. Нуріманов, Т. В. Порошина, В. С. Савченко, Г. М. Драннік

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The journal does not require authors of original (primary) research papers to assign the copyright of their published contributions. Authors grant the journal an non-exclusive licence CC BY 4.0 (Creative Commons Attribution 4.0 International License) to using and the first publication of the original in this journal. Copyright of the manuscripts is retained by the authors, after publication authors retain rights to reuse their papers in their future printed work without first requiring permission from the publisher of the journal and share their own published articles.
The journal supports the self-archiving process. Prior to publication in the journal, authors may post a copy of their manuscript in preparation or submitted to the journal in recognized non-commercial preprint servers, public websites. Authors also are encouraged to archive their final author version of the manuscript in their institution's repositories and, if they wish, on their personal websites. Authors should cite the publication reference and DOI number on the first page of any deposited version, and provide a link from it to the URL of the published article on the journal's website.
To facilitate self-archiving of original research papers and help authors fulfil funder and institutional mandates, the journal deposits manuscripts in National Library of Ukraine by V.I. Vernadsky, Scientific periodicals of Ukraine database and different international scintificd database on behalf of authors who opt-in to this free service during submission. The journal provides depositing of articles on official website of the publisher. The full text access to published papers is free.